ERCC3 and prostate carcinoma: It inhibits the phosphorylation of AR and its castration-resistant variant AR-V7 at Ser515 via XPB/CDK7, enhancing the anti-prostate cancer activity of enzalutamide in castration-resistant prostate cancer (Han et al., 2017).